3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Active not recruiting
2
Available
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Recurrence
1
Neoplasm, Residual
1
Lymphoma, Follicular
1
Burkitt Lymphoma
1
Interventions
Specimen Handling
218
Magnetic Resonance Spectroscopy
194
pembrolizumab
185
Carboplatin
160
Biopsy
129
Cisplatin
128
Nivolumab
119
Paclitaxel
107
Cyclophosphamide
104
Radiotherapy
99
Gemcitabine
96
Dexamethasone
86
durvalumab
83
atezolizumab
70
Rituximab
66
Radiation
64
Lenalidomide
64
Doxorubicin
63
Pemetrexed
61
Bevacizumab
58
Etoposide
56
Docetaxel
56
olaparib
50
Ipilimumab
49
Fluorouracil
48
Taxes
47
Prednisone
47
Oxaliplatin
46
Vincristine
45
Cytarabine
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
tisagenlecleucel
×
90 days
×
Clear all
NCT03876769
2026-06-02
CASSIOPEIA
Novartis
Phase 2
Active not recruiting
121 enrolled
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled